Holen Sie sich die Stockscreener-App
22.09
2.03%
0.44
Schlusskurs vom Vortag:
$21.65
Offen:
$21.94
24-Stunden-Volumen:
1.02M
Relative Volume:
0.90
Marktkapitalisierung:
$2.39B
Einnahmen:
$577.74M
Nettoeinkommen (Verlust:
$-149.78M
KGV:
-15.78
EPS:
-1.4
Netto-Cashflow:
$-78.21M
1W Leistung:
-1.73%
1M Leistung:
-18.06%
6M Leistung:
+26.23%
1J Leistung:
+41.42%
1-Tages-Spanne:
$21.38
$22.14
1-Wochen-Bereich:
$21.38
$22.56
52-Wochen-Spanne:
$11.70
$34.13
Novocure Ltd Stock (NVCR) Company Profile
Firmenname
Novocure Ltd
Sektor
Branche
Telefon
44 (0)15 3475 6700
Adresse
NO. 4 THE FORUM, ST. HELIER
Vergleichen Sie NVCR mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
NVCR
Novocure Ltd
|
22.09 | 2.39B | 577.74M | -149.78M | -78.21M | -1.40 |
|
ABT
Abbott Laboratories
|
134.92 | 234.01B | 41.95B | 13.40B | 6.49B | 7.65 |
|
BSX
Boston Scientific Corp
|
104.49 | 154.20B | 16.75B | 1.85B | 2.37B | 1.25 |
|
SYK
Stryker Corp
|
382.78 | 146.06B | 22.60B | 2.99B | 3.49B | 7.76 |
|
MDT
Medtronic Plc
|
89.94 | 115.42B | 33.20B | 4.26B | 5.47B | 3.29 |
|
EW
Edwards Lifesciences Corp
|
73.30 | 43.23B | 5.72B | 4.17B | 490.10M | 6.97 |
Novocure Ltd Stock (NVCR) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-12-02 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2024-10-16 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2023-11-20 | Fortgesetzt | JP Morgan | Neutral |
| 2023-08-28 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2023-08-08 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2023-08-04 | Eingeleitet | SVB Securities | Outperform |
| 2023-07-31 | Hochstufung | Evercore ISI | Underperform → In-line |
| 2023-06-07 | Hochstufung | Wedbush | Underperform → Neutral |
| 2023-05-16 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2023-03-17 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2023-01-06 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2023-01-05 | Bestätigt | H.C. Wainwright | Buy |
| 2022-11-29 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2022-10-24 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2022-07-05 | Herabstufung | Evercore ISI | In-line → Underperform |
| 2022-05-16 | Eingeleitet | H.C. Wainwright | Buy |
| 2022-02-08 | Eingeleitet | Loop Capital | Buy |
| 2022-02-02 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2022-01-20 | Hochstufung | Truist | Hold → Buy |
| 2022-01-03 | Hochstufung | Evercore ISI | Underperform → In-line |
| 2021-07-01 | Herabstufung | Mizuho | Buy → Neutral |
| 2021-04-14 | Herabstufung | Wedbush | Neutral → Underperform |
| 2021-01-25 | Bestätigt | Piper Sandler | Overweight |
| 2020-09-23 | Eingeleitet | Northland Capital | Outperform |
| 2020-09-18 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2020-09-17 | Herabstufung | Truist | Buy → Hold |
| 2020-06-01 | Fortgesetzt | Oppenheimer | Perform |
| 2020-05-01 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2020-04-09 | Herabstufung | Evercore ISI | In-line → Underperform |
| 2020-03-05 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2020-01-02 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2019-07-29 | Hochstufung | SunTrust | Hold → Buy |
| 2019-07-26 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2019-07-26 | Herabstufung | Wedbush | Outperform → Neutral |
| 2019-03-20 | Eingeleitet | SunTrust | Hold |
| 2018-11-02 | Herabstufung | Wells Fargo | Outperform → Market Perform |
| 2018-07-16 | Eingeleitet | Evercore ISI | Outperform |
| 2018-04-18 | Bestätigt | Mizuho | Buy |
| 2018-02-23 | Bestätigt | Mizuho | Buy |
| 2017-05-24 | Hochstufung | Wells Fargo | Market Perform → Outperform |
| 2016-07-29 | Bestätigt | Wedbush | Outperform |
| 2016-01-19 | Eingeleitet | Barclays | Underweight |
| 2015-12-02 | Eingeleitet | Deutsche Bank | Hold |
Alle ansehen
Novocure Ltd Aktie (NVCR) Neueste Nachrichten
NovoCure Limited (NASDAQ:NVCR) Shares Sold by Baillie Gifford & Co. - MarketBeat
NovoCure (NVCR) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release - Yahoo Finance
NovoCure (NVCR) Projected to Post Earnings on Thursday - MarketBeat
Legato Capital Management LLC Sells 19,107 Shares of NovoCure Limited (NASDAQ:NVCR) - MarketBeat
Choreo LLC Makes New Investment in NovoCure Limited (NASDAQ:NVCR) - Defense World
Does NovoCure (NASDAQ:NVCR) Have A Healthy Balance Sheet? - Simply Wall St
An Analysis of NovoCure Ltd (NVCR)’s Potential Price Growth - Knox Daily
Novocure Rings the Nasdaq Stock Market Opening Bell - Nasdaq
NovoCure Ltd (NVCR) Has Recovered 47.42% From Its Low: Is This The Beginning Of A Trend? - Stocks Register
NovoCure Limited (NASDAQ:NVCR) Shares Purchased by KBC Group NV - Defense World
What was NovoCure Ltd (NVCR)’s performance in the last session? - US Post News
Evercore ISI Upgrades NovoCure Ltd (NVCR) to an Outperform from an In-line - Knox Daily
Financial Snapshot: Analyzing Spectral AI Inc (MDAI)’s Key Ratio Metrics - The Dwinnex
Ratio Examination: NovoCure Ltd (NVCR)’s Price-to-Cash and Price-to-Free Cash Flow - The Dwinnex
Exchange Traded Concepts LLC Has $859,000 Stock Holdings in NovoCure Limited (NASDAQ:NVCR) - MarketBeat
NovoCure Ltd (NVCR) Should Be Considered Now, Despite A Loss Of -28.16% From High - Stocks Register
Nisa Investment Advisors LLC Grows Position in NovoCure Limited (NASDAQ:NVCR) - Defense World
Jim Cramer Likes This Tech Stock: 'Terrific Business, Niche Business' - Benzinga
NovoCure Limited (NASDAQ:NVCR) Given Consensus Rating of “Moderate Buy” by Brokerages - Defense World
Brokerages Set NovoCure Limited (NASDAQ:NVCR) PT at $32.67 - MarketBeat
NovoCure Ltd (NASDAQ: NVCR): Overvalued In Comparison To Others? - Stocks Register
NovoCure (NASDAQ:NVCR) Stock Price Crosses Above 50-Day Moving AverageWhat's Next? - MarketBeat
Novocure Ltd. to Host Earnings Call - ACCESS Newswire
Novocure Inaugurates New Global Headquarters in Canton of Zug, Switzerland - Yahoo Finance
Investing in NovoCure (NASDAQ:NVCR) a year ago would have delivered you a 85% gain - Yahoo Finance
Novocure gets approval for rooftop penthouse at downtown Portsmouth headquarters - AOL
FY2024 EPS Estimates for NovoCure Lifted by HC Wainwright - Defense World
HC Wainwright Increases Earnings Estimates for NovoCure - MarketBeat
NovoCure’s (NVCR) Buy Rating Reiterated at HC Wainwright - Defense World
Wedbush Has Positive Outlook of NovoCure FY2024 Earnings - Defense World
HC Wainwright Forecasts NovoCure FY2029 Earnings - Defense World
HC Wainwright Predicts NovoCure FY2029 Earnings - MarketBeat
Wedbush Comments on NovoCure's FY2024 Earnings (NASDAQ:NVCR) - MarketBeat
Novocure's COO Mukund Paravasthu sells $57,906 in shares By Investing.com - Investing.com South Africa
Novocure's COO Mukund Paravasthu sells $57,906 in shares - Investing.com India
NovoCure Ltd (NVCR) Shares Down 3.67% on Jan 14 - GuruFocus.com
NovoCure (NASDAQ:NVCR) Given Buy Rating at HC Wainwright - MarketBeat
Deep Dive Into NovoCure Stock: Analyst Perspectives (7 Ratings) - Benzinga
NovoCure’s (NVCR) Neutral Rating Reaffirmed at Wedbush - Defense World
NovoCure's (NVCR) Neutral Rating Reiterated at Wedbush - MarketBeat
Is Now The Time To Buy NovoCure Ltd (NASDAQ: NVCR) Stock? - Stocks Register
Novocure reports revenue growth, FDA approvals in 2024 - Investing.com India
Novocure Reports Strong 19% Revenue Growth, Hits $605M as Cancer Treatment Platform Expands - StockTitan
Investing in NovoCure (NASDAQ:NVCR) a year ago would have delivered you a 97% gain - Simply Wall St
NovoCure Limited (NASDAQ:NVCR) Shares Acquired by Versant Capital Management Inc - Defense World
NovoCure Limited (NASDAQ:NVCR) Receives $32.67 Average PT from Brokerages - MarketBeat
NovoCure Limited (NASDAQ:NVCR) Receives Average Recommendation of “Moderate Buy” from Brokerages - Defense World
Novocure CEO to Present at J.P. Morgan Healthcare Conference, Announces Investor Meetings - StockTitan
Novocure to Participate in 43rd Annual J.P. Morgan Healthcare Conference - Yahoo Finance
NovoCure Limited (NASDAQ:NVCR) Shares Acquired by Franklin Resources Inc. - MarketBeat
Finanzdaten der Novocure Ltd-Aktie (NVCR)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.16%
0.10%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):